YMTX yields 105.82% · STAG yields 3.99%● Live data
📍 YMTX pulled ahead of the other in Year 1
Combined, YMTX + STAG cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YMTX + STAG for your $10,000?
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Full YMTX Calculator →STAG Industrial is a single-tenant industrial REIT paying monthly dividends. Its portfolio of 500+ warehouses and distribution centers benefits from e-commerce growth. Amazon is its largest tenant. Monthly income frequency makes it attractive for investors who prefer regular cash flow over quarterly payments.
Full STAG Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.